Back to News
Sep 19, 2025 4:00 PM

Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug

On Friday, a European agency adopted two positive opinions for Merck & Co. Inc.’s (NYSE:MRK) Keytruda (pembrolizumab).

One opinion recommends approval of a new subcutaneous (SC) administration route and a solution for injection formulation. If approved, Keytruda SC could be administered in one minute every three weeks (395 mg) or two minutes every six weeks (790 mg).

Read Next: Merck’s Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs

What Happened: The positive take from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) applies to all KEYTRUDA indications for adult patients in Europe.

The marketing ...